2breathe Technologies Ltd with its wholly owned US subsidiary Resperate Inc announced publication of a peer-reviewed original article with the results from a 96 heart failure patients study. The study used the company’s FDA-cleared hypertension treatment device, RESPeRATE. The study demonstrated that using RESPerATE during 12-weeks in the home setting can improve exercise capacity, left ventricular function, accompanied by a reduction in end-diastolic diameter of the left ventricle and attenuation of sleep disturbances, mainly central apnea.
The study was led by Kalina Kawecka-Jaszcz from the Department of Cardiology at the Jagiellonian University Medical College, Krako?w, Poland, in collaboration with Gianfranco Parati, professor of Cardiovascular Medicine at the Univeristy of Milano-Bicocca and head of Cardiology Department, S.Luca Hospital, Istituto Auxologico Italiano, Milan, Italy.
“Chronic heart failure has become one of the most widespread diseases and a principal cause of morbidity and mortality in aging societies, due to the high prevalence of its main causes, namely, hypertension and coronary heart disease,” says Parati, a cardiologist and expert in the arena of telemedicine and digital therapeutics, in a release. “These new study results are consistent with two earlier randomized controlled studies supporting the benefits of RESPeRATE as a novel component of cardiorespiratory rehabilitation programs in patients with CHF.”
“The results of these independent studies on heart failure patients and sleep disordered breathing in particular, expand the growing body of scientific evidence that the benefits of RESPeRATE extend beyond hypertension,” says Erez Gavish, co-founder/CEO of 2breathe technologies. “As a digital therapeutic device, RESPeRATE goes beyond patient monitoring to encourage compliance and offer a powerful non-drug therapeutic option that improves patient lives. It’s a very exciting future.”